Dacinostat (LAQ824)

Synonyms: NVP-LAQ824

Dacinostat (LAQ824, NVP-LAQ824) is a novel HDAC inhibitor with IC50 of 32 nM and is known to activate the p21 promoter.

Dacinostat (LAQ824) Chemical Structure

Dacinostat (LAQ824) Chemical Structure

CAS: 404951-53-7

Selleck's Dacinostat (LAQ824) has been cited by 21 Publications

5 Customer Reviews

Purity & Quality Control

Batch: Purity: 99.17%
99.17

Dacinostat (LAQ824) Related Products

Signaling Pathway

Choose Selective HDAC Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1299 Growth inhibition assay Inhibitory activity against H1299 human lung carcinoma cell growth, IC50=0.15 μM 14521422
HCT116 Growth inhibition assay Inhibitory activity against HCT116 human colon cell growth, IC50=0.01 μM 14521422
HCT116 Cytotoxicity assay Cytotoxicity against human HCT116 cells by MTT assay, IC50=0.05 μM 17941625
human mammary epithelial cells Cytotoxicity assay Cytotoxicity against human mammary epithelial cells by MTT assay, IC50=1 μM 17941625
HEK293 cells Function assay Inhibition of HDAC1 in HEK293 cells, IC50=0.0026 μM 18308563
HeLa cells Function assay 0.3 μM 16 h Inhibition of HDAC4-mediated repression of MEF2-dependent transcription in HeLa cells at 0.3 uM after 16 hrs by luciferase reporter gene assay 17956988
HCT116 cells Proliferation assay Antiproliferative activity against human HCT116 cells by MTS assay, IC50=0.013 μM 20205394
H1299 cells Proliferation assay Antiproliferative activity against human H1299 cells by MTS assay, IC50=0.161 μM 20205394
H460 cells Growth inhibition assay 48 h Growth inhibition of human H460 cells after 48 hrs by SRB assay, IC50=0.07 μM 21073160
HCT116 cells Growth inhibition assay 48 h Growth inhibition of human HCT116 cells after 48 hrs by SRB assay, IC50=0.018 μM 21073160
CCRF-CEM cells Proliferation assay Antiproliferative activity against human CCRF-CEM cells by SRB assay, GI50=0.251 μM 21621883
K562 cells Proliferation assay Antiproliferative activity against human K562 cells by SRB assay, GI50=0.55 μM 21621883
MOLT4 cells Proliferation assay Antiproliferative activity against human MOLT4 cells by SRB assay, GI50=0.311 μM 21621883
SR cells Proliferation assay Antiproliferative activity against human SR cells by SRB assay, GI50=2.99 μM 21621883
A549 cells Proliferation assay Antiproliferative activity against human A549 cells by SRB assay, GI50=1.09 μM 21621883
EKVX cells Proliferation assay Antiproliferative activity against human EKVX cells by SRB assay, GI50=1.75 μM 21621883
HOP62 cells Proliferation assay Antiproliferative activity against human HOP62 cells by SRB assay, GI50=0.502 μM 21621883
HOP92 cells Proliferation assay Antiproliferative activity against human HOP92 cells by SRB assay, GI50=0.199 μM 21621883
NCI-H226 cells Proliferation assay Antiproliferative activity against human NCI-H226 cells by SRB assay, GI50=1.41 μM 21621883
NCI-H23 cells Proliferation assay Antiproliferative activity against human NCI-H23 cells by SRB assay, GI50=1.5 μM 21621883
NCI-H322M cells Proliferation assay Antiproliferative activity against human NCI-H322M cells by SRB assay, GI50=2.26 μM 21621883
NCI-H460 cells Proliferation assay Antiproliferative activity against human NCI-H460 cells by SRB assay, GI50=0.7 μM 21621883
COLO205 cells Proliferation assay Antiproliferative activity against human COLO205 cells by SRB assay, GI50=1.08 μM 21621883
HCT116 cells Proliferation assay Antiproliferative activity against human HCT116 cells by SRB assay, GI50=0.347 μM 21621883
HCT15 cells Proliferation assay Antiproliferative activity against human HCT15 cells by SRB assay, GI50=2.07 μM 21621883
HT-29 cells Proliferation assay Antiproliferative activity against human HT-29 cells by SRB assay, GI50=0.566 μM 21621883
KM12 cells Proliferation assay Antiproliferative activity against human KM12 cells by SRB assay, GI50=1.04 μM 21621883
SW620 cells Proliferation assay Antiproliferative activity against human SW620 cells by SRB assay, GI50=0.478 μM 21621883
SF268 cells Proliferation assay Antiproliferative activity against human SF268 cells by SRB assay, GI50=1.53 μM 21621883
SF295 cells Proliferation assay Antiproliferative activity against human SF295 cells by SRB assay, GI50=0.743 μM 21621883
SF539 cells Proliferation assay Antiproliferative activity against human SF539 cells by SRB assay, GI50=0.965 μM 21621883
SNB19 cells Proliferation assay Antiproliferative activity against human SNB19 cells by SRB assay, GI50=1.53 μM 21621883
SNB75 cells Proliferation assay Antiproliferative activity against human SNB75 cells by SRB assay, GI50=0.318 μM 21621883
U251 cells Proliferation assay Antiproliferative activity against human U251 cells by SRB assay, GI50=0.773 μM 21621883
LOXIMVI cells Proliferation assay Antiproliferative activity against human LOXIMVI cells by SRB assay, GI50=1.08 μM 21621883
MALME-3M cells Proliferation assay Antiproliferative activity against human MALME-3M cells by SRB assay, GI50=0.461 μM 21621883
M14 cells Proliferation assay Antiproliferative activity against human M14 cells by SRB assay, GI50=0.849 μM 21621883
MDA-MB-435 cells Proliferation assay Antiproliferative activity against human MDA-MB-435 cells by SRB assay, GI50=0.537 μM 21621883
SK-MEL-28 cells Proliferation assay Antiproliferative activity against human SK-MEL-28 cells by SRB assay, GI50=0.993 μM 21621883
SK-MEL-5 cells Proliferation assay Antiproliferative activity against human SK-MEL-5 cells by SRB assay, GI50=0.271 μM 21621883
UACC257 cells Proliferation assay Antiproliferative activity against human UACC257 cells by SRB assay, GI50=0.393 μM 21621883
UACC62 cells Proliferation assay Antiproliferative activity against human UACC62 cells by SRB assay, GI50=0.379 μM 21621883
IGROV1 cells Proliferation assay Antiproliferative activity against human IGROV1 cells by SRB assay, GI50=0.187 μM 21621883
OVCAR3 cells Proliferation assay Antiproliferative activity against human OVCAR3 cells by SRB assay, GI50=1.11 μM 21621883
OVCAR4 cells Proliferation assay Antiproliferative activity against human OVCAR4 cells by SRB assay, GI50=3.21 μM 21621883
OVCAR5 cells Proliferation assay Antiproliferative activity against human OVCAR5 cells by SRB assay, GI50=0.26 μM 21621883
OVCAR8 cells Proliferation assay Antiproliferative activity against human OVCAR8 cells by SRB assay, GI50=0.45 μM 21621883
NCI/ADR-RES cells Proliferation assay Antiproliferative activity against human NCI/ADR-RES cells by SRB assay, GI50=0.18 μM 21621883
SKOV3 cells Proliferation assay Antiproliferative activity against human SKOV3 cells by SRB assay, GI50=0.524 μM 21621883
786-0 cells Proliferation assay Antiproliferative activity against human 786-0 cells by SRB assay, GI50=2.38 μM 21621883
A498 cells Proliferation assay Antiproliferative activity against human A498 cells by SRB assay, GI50=1.11 μM 21621883
ACHN cells Proliferation assay Antiproliferative activity against human ACHN cells by SRB assay, GI50=1.1 μM 21621883
Caki1 cells Proliferation assay Antiproliferative activity against human Caki1 cells by SRB assay, GI50=0.619 μM 21621883
SN12C cells Proliferation assay Antiproliferative activity against human SN12C cells by SRB assay, GI50=3.92 μM 21621883
TK10 cells Proliferation assay Antiproliferative activity against human TK10 cells by SRB assay, GI50=0.444 μM 21621883
UO31 cells Proliferation assay Antiproliferative activity against human UO31 cells by SRB assay, GI50=0.452 μM 21621883
PC3 cells Proliferation assay Antiproliferative activity against human PC3 cells by SRB assay, GI50=20 μM 21621883
DU145 cells Proliferation assay Antiproliferative activity against human DU145 cells by SRB assay, GI50=29.9 μM 21621883
MCF7 cells Proliferation assay Antiproliferative activity against human MCF7 cells by SRB assay, GI50=6.91 μM 21621883
MDA-MB-231 cells Proliferation assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay, GI50=31.7 μM 21621883
Hs 578T cells Proliferation assay Antiproliferative activity against human Hs 578T cells by SRB assay, GI50=5.82 μM 21621883
BT549 cells Proliferation assay Antiproliferative activity against human BT549 cells by SRB assay, GI50=6.04 μM 21621883
T47D cells Proliferation assay Antiproliferative activity against human T47D cells by SRB assay, GI50=28.8 μM 21621883
MDA-MB-468 cells Proliferation assay Antiproliferative activity against human MDA-MB-468 cells by SRB assay, GI50=5.88 μM 21621883
NCI-H226 cells Cytotoxicity assay Cytotoxicity against human NCI-H226 cells, LC50=20 μM 21621883
KM12 cells Cytotoxicity assay Cytotoxicity against human KM12 cells, LC50=29.9 μM 21621883
SF295 cells Cytotoxicity assay Cytotoxicity against human SF295 cells, LC50=6.91 μM 21621883
SNB19 cells Cytotoxicity assay Cytotoxicity against human SNB19 cells, LC50=31.7 μM 21621883
U251 cells Cytotoxicity assay Cytotoxicity against human U251 cells, LC50=5.82 μM 21621883
LOXIMVI cells Cytotoxicity assay Cytotoxicity against human LOXIMVI cells, LC50=6.04 μM 21621883
MDA-MB-435 cells Cytotoxicity assay Cytotoxicity against human MDA-MB-435 cells, LC50=28.8 μM 21621883
SK-MEL-28 cells Cytotoxicity assay Cytotoxicity against human SK-MEL-28 cells, LC50=31.9 μM 21621883
SK-MEL-5 cells Cytotoxicity assay Cytotoxicity against human SK-MEL-5 cells, LC50=4.02 μM 21621883
UACC257 cells Cytotoxicity assay Cytotoxicity against human UACC257 cells, LC50=44.8 μM 21621883
UACC62 cells Cytotoxicity assay Cytotoxicity against human UACC62 cells, LC50=6.39 μM 21621883
IGROV1 cells Cytotoxicity assay Cytotoxicity against human IGROV1 cells, LC50=48.9 μM 21621883
OVCAR5 cells Cytotoxicity assay Cytotoxicity against human OVCAR5 cells, LC50=38.9 μM 21621883
SKOV3 cells Cytotoxicity assay Cytotoxicity against human SKOV3 cells, LC50=28.5 μM 21621883
A498 cells Cytotoxicity assay Cytotoxicity against human A498 cells, LC50=5.88 μM 21621883
Caki1 cells Cytotoxicity assay Cytotoxicity against human Caki1 cells, LC50=5.79 μM 21621883
HCT116 cells Proliferation assay Antiproliferative activity against human HCT116 cells, IC50=0.019 μM 21742496
HCT116 cells Proliferation assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition, IC50=0.019 μM 21650221
H1299 cells Proliferation assay Antiproliferative activity against human H1299 cells, IC50=0.1 μM 21650221
HCT116 cells Proliferation assay Inhibitory concentration against HCT116 cells proliferation, IC50=0.01 μM 14613312
RPMI8226 cells Proliferation assay Antiproliferative activity against human RPMI8226 cells by SRB assay, GI50=0.523 μM 21621883
CHO cells Function assay Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay, IC50=12.2 μM 20205394
HL-60(TB) cells Proliferation assay Antiproliferative activity against human HL-60(TB) cells by SRB assay, GI50=0.249 μM 21621883
RXF393 cells Proliferation assay Antiproliferative activity against human RXF393 cells by SRB assay, GI50=0.01 μM 21621883
RXF393 cells Cytotoxicity assay Cytotoxicity against human RXF393 cells, LC50=15.3 μM 21621883
Click to View More Cell Line Experimental Data

Biological Activity

Description Dacinostat (LAQ824, NVP-LAQ824) is a novel HDAC inhibitor with IC50 of 32 nM and is known to activate the p21 promoter.
Targets
p21 [1] HDAC [1]
(Cell-free assay)
32 nM
In vitro
In vitro LAQ824 activates the expression of the gene encoding the p21 cell cycle inhibitor by activating the p21 promoter with 50% of the maximal promoter activation (AC50) of 0.30 μM. LAQ824 inhibits the cell growth of both H1299, a non-small cell lung carcinoma line, and HCT116, a colon cancer cell line with IC50 of 0.15 μM and 0.01 μM, respectively, and the antiproliferative effect of LAQ824 is selective toward the tumor cell lines while inducing only growth arrest in normal fibroblasts. Furthermore, LAQ824 induces a dose-dependent increase of p21 protein in A549 cells and an increase in the hypophosphorylated state of the Rb tumor suppressor. [1] A recent study shows that LAQ824 induces chromatin changes at the level of the IL-10 gene promoter that lead to enhanced recruitment of the transcriptional repressors HDAC11 and PU.1 and inhibits IL-10 production in BALB/c murine macrophages. [2]
Kinase Assay In Vitro Histone Deacetylase Assay
HDAC enzymes are partially purified from H1299 cell lysate by ion exchange chromatography using the Q Sepharose Fast Flow column. Enzyme complexes are collected from 500 mg of total cell lysate by immunoprecipitation with cdk2 polyclonal antibody or cdk1/cdc2 monoclonal antibody. Immunoprecipitates are resuspended in kinase buffer (50 mM Hepes, pH 8, 10 mM MgCl2, 2.5 mM EDTA, 1 mM dithiothreitol, 20 mM ATP, 10 mM β-glycerophosphate, 0.1 mM NaVO4, 1 mM sodium fluoride, 50 mM ATP, 10 μCi of [γ-32P]ATP) along with 1 μg of pRb recombinant protein substrate (cdk2) or 10 mL of H1 histone mixture containing 20 μg of substrate (cdc2). Phosphorylated Rb and H1 histone are resolved by electrophoresis and quantitated using a PhosphorImager.
Cell Research Cell lines H1299, HCT116, DU145, PC3 and MDA435 cells
Concentrations 0-10 μM
Incubation Time 48 hours
Method Cell proliferation is measured using an adaptation of published procedures (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfonyl)-2H-tetrazolium assay). The cells are seeded in 12-well dishes and cultured in RPMI 1640 containing 10% FBS. The cells are cultured in the presence of various concentrations of TSA (up to 1,000 ng/mL). To examine the growth inhibition by TSA, viable cell numbers are determined by trypan blue dye exclusion, counted in a Nesbauer-type hemocytometer for 0 hour, 24 hours, and 48 hours. The same amount of ethanol is added to the RPMI 1640 medium as the control experiment. All experiments are performed in duplicate and repeated 3 times The average background value (treatment with medium alone) is subtracted from each experimental well; triplicate values are averaged for each compound dilution. The following formulas are used to calculate the percentage of growth: If X0, %Growth=(X-T0)/T0*100; If X>T0, %Growth=(X-T0)/(GC-T0)*100. where T0 is the average value of T0 − background, GC is the average value of untreated cells (in triplicate) − background, and X is the average value of compound-treated cells (in triplicate)-background. The “% Growth” is plotted against compound concentration and used to calculate the IC50 using the linear regression techniques between data points to predict the concentration of compounds at 50% inhibition.
In Vivo
In vivo In HCT116 and human colon tumor xenografts in nude mice, LAQ824 treatment at 100 mg/kg produces the inhibitory effects on tumor growth in a dose-dependent mode without general cytotoxicity. [1]
Animal Research Animal Models HCT116 cells is injected s.c. into the right axillary (lateral) region of outbred athymic (nu/nu) female mice.
Dosages ≤100 mg/kg
Administration Administered via i.v.

Chemical Information & Solubility

Molecular Weight 379.459 Formula

C22H25N3O3

CAS No. 404951-53-7 SDF Download Dacinostat (LAQ824) SDF
Smiles C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)C=CC(=O)NO
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 76 mg/mL ( (200.28 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Dacinostat (LAQ824) | Dacinostat (LAQ824) supplier | purchase Dacinostat (LAQ824) | Dacinostat (LAQ824) cost | Dacinostat (LAQ824) manufacturer | order Dacinostat (LAQ824) | Dacinostat (LAQ824) distributor